- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02477826
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Córdoba, Argentina, 5016
- Local Institution - 0272
-
Córdoba, Argentina, X50004FHP
- Local Institution - 0297
-
Córdoba, Argentina, 5000
- Local Institution - 0268
-
Viedma, Argentina, 8500
- Local Institution - 0177
-
-
Buenos Aires
-
Berazategui, Buenos Aires, Argentina, 1880
- Local Institution - 0170
-
Capital Federal, Buenos Aires, Argentina, 1426
- Local Institution - 0171
-
Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina, 1181
- Local Institution - 0172
-
Ciudad de Buenos Aires, Buenos Aires, Argentina, 1025
- Local Institution - 0176
-
Mar del Plata, Buenos Aires, Argentina, 7600
- Local Institution - 0296
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Argentina, 4000
- Local Institution - 0130
-
-
-
-
-
Murdoch, Australia, 6150
- Local Institution - 0040
-
North Tamworth, Australia, 2340
- Local Institution - 0183
-
-
Australian Capital Territory
-
Garran, Australian Capital Territory, Australia, 2605
- Local Institution - 0182
-
-
New South Wales
-
Blacktown, New South Wales, Australia, 2148
- Local Institution - 0301
-
Gosford, New South Wales, Australia, 2250
- Local Institution - 0300
-
-
Queensland
-
Brisbane, Queensland, Australia, 4102
- Local Institution - 0045
-
-
South Australia
-
Elizabeth Vale, South Australia, Australia, 5112
- Local Institution - 0046
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Local Institution - 0043
-
Fitzroy, Victoria, Australia, 3065
- Local Institution - 0042
-
-
Western Australia
-
Perth, Western Australia, Australia, 6150
- Local Institution - 0180
-
-
-
-
-
Graz, Austria, 8036
- Local Institution - 0241
-
Vienna, Austria, 1090
- Local Institution - 0240
-
Wels, Austria, 4600
- Local Institution - 0239
-
-
-
-
-
Edegem, Belgium, 2650
- Local Institution - 0030
-
Ghent, Belgium, 9000
- Local Institution - 0031
-
Hasselt, Belgium, 3500
- Local Institution - 0117
-
Sint-Niklaas, Belgium, 9100
- Local Institution - 0033
-
-
Hainaut
-
Charleroi, Hainaut, Belgium, 6060
- Local Institution - 0034
-
-
West-Vlaanderen
-
Roeselare, West-Vlaanderen, Belgium, 8800
- Local Institution - 0121
-
-
-
-
-
Rio de Janeiro, Brazil, 20231-050
- Local Institution - 0129
-
São Paulo, Brazil, 01321-001
- Local Institution - 0144
-
São Paulo, Brazil, 01509-010
- Local Institution - 0126
-
São Paulo, Brazil, 05403-010
- Local Institution - 0128
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brazil, 40170-110
- Local Institution - 0125
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, Brazil, 98700-000
- Local Institution - 0124
-
Porto Alegre, Rio Grande do Sul, Brazil, 90610-000
- Local Institution - 0123
-
-
São Paulo
-
Barretos, São Paulo, Brazil, 14784-400
- Local Institution - 0127
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Local Institution - 0103
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Local Institution - 0290
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Local Institution - 0104
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Local Institution - 0122
-
Québec, Quebec, Canada, G1J 1Z4
- Local Institution - 0106
-
Québec, Quebec, Canada, G1V 4G5
- Local Institution - 0302
-
Rimouski, Quebec, Canada, G5L 5T1
- Local Institution - 0107
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Local Institution - 0291
-
Trois-Rivières, Quebec, Canada, G8Z 3R9
- Local Institution - 0292
-
-
-
-
Región de Valparaíso
-
Viña del Mar, Región de Valparaíso, Chile, 254 0364
- Local Institution - 0174
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chile, 7500921
- Local Institution - 0173
-
Santiago, Santiago Metropolitan, Chile, 8420383
- Local Institution - 0131
-
-
-
-
-
Changsha, China
- Local Institution - 0328
-
Hangzhou, China, 310016
- Local Institution - 0341
-
Kunming, China
- Local Institution - 0345
-
Shanghai, China, 200030
- Local Institution - 0337
-
Shantou, China
- Local Institution - 0374
-
-
Anhui
-
Hefei, Anhui, China, 230001
- Local Institution - 0380
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100001
- Local Institution - 0313
-
Beijing, Beijing Municipality, China, 100021
- Local Institution - 0315
-
Beijing, Beijing Municipality, China, 100021
- Local Institution - 0316
-
Beijing, Beijing Municipality, China, 100032
- Local Institution - 0314
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400037
- Local Institution - 0365
-
Chongqing, Chongqing Municipality, China, 400038
- Local Institution - 0364
-
Chongqing, Chongqing Municipality, China, 400042
- Local Institution - 0378
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Local Institution - 0322
-
Guangzhou, Guangdong, China, 510095
- Local Institution - 0372
-
Guanzhou, Guangdong, China, 510080
- Local Institution - 0319
-
-
Hainan
-
Haikou, Hainan, China, 570311
- Local Institution - 0323
-
-
Heilongjiang
-
Haerbin, Heilongjiang, China, 150081
- Local Institution - 0325
-
-
Henan
-
Zhengzhou, Henan, China
- Local Institution - 0324
-
Zhengzhou, Henan, China, 450052
- Local Institution - 0379
-
-
Hubei
-
Wuhan, Hubei, China, 430024
- Local Institution - 0375
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Local Institution - 0362
-
-
Jiangxi
-
Nanchang, Jiangxi, China
- Local Institution - 0347
-
-
Jilin
-
Changchun, Jilin, China, 130012
- Local Institution - 0329
-
Changchun, Jilin, China, 130021
- Local Institution - 0361
-
-
Liaoning
-
Shenyang, Liaoning, China, 110000
- Local Institution - 0359
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- Local Institution - 0371
-
-
Shan3xi
-
Xi'an, Shan3xi, China, 710038
- Local Institution - 0333
-
-
Shandong
-
Qingdao, Shandong, China, 266061
- Local Institution - 0360
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200030
- Local Institution - 0336
-
Shanghai, Shanghai Municipality, China, 200032
- Local Institution - 0334
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Local Institution - 0376
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300060
- Local Institution - 0373
-
-
Xinjiang
-
Ürümqi, Xinjiang, China, 830011
- Local Institution - 0340
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Local Institution - 0343
-
Hangzhou, Zhejiang, China, 310009
- Local Institution - 0370
-
Hangzhou, Zhejiang, China, 310022
- Local Institution - 0342
-
-
-
-
-
Bogotá, Colombia
- Local Institution - 0237
-
Bogotá, Colombia
- Local Institution - 0238
-
Medellín, Colombia, 050034
- Local Institution - 0282
-
-
Risaralda Department
-
Pereira, Risaralda Department, Colombia
- Local Institution - 0273
-
-
-
-
-
Hradec Králové, Czechia, 500 05
- Local Institution - 0112
-
Olomouc, Czechia, 779 00
- Local Institution - 0113
-
Prague, Czechia, 140 59
- Local Institution - 0111
-
Příbram, Czechia, 261 01
- Local Institution - 0232
-
-
-
-
-
Oulu, Finland, 90029
- Local Institution - 0270
-
Turku, Finland, 20520
- Local Institution - 0271
-
-
-
-
-
Angers, France, 49055
- Local Institution - 0216
-
Besançon, France
- Local Institution - 0229
-
Caen, France, 14076
- Local Institution - 0283
-
Créteil, France, 94010
- Local Institution - 0218
-
Limoges, France, 87042
- Local Institution - 0228
-
Marseille, France, 13915
- Local Institution - 0215
-
Paris, France, 75018
- Local Institution - 0230
-
Pessac, France, 33604
- Local Institution - 0227
-
Rennes, France, 350330
- Local Institution - 0223
-
Rouen, France, 76000
- Local Institution - 0225
-
Saint-Herblain, France, 44805
- Local Institution - 0217
-
Saint-Priest-en-Jarez, France, 42271
- Local Institution - 0221
-
Strasbourg, France, 67000
- Local Institution - 0224
-
Toulon, France, 83056
- Local Institution - 0226
-
-
Rhône
-
Bron, Rhône, France, 69677
- Local Institution - 0222
-
-
-
-
-
Bad Berka, Germany, 99437
- Local Institution - 0213
-
Berlin, Germany, 13125
- Local Institution - 0208
-
Essen, Germany, 45147
- Local Institution - 0205
-
Frankfurt, Germany, 60590
- Local Institution - 0210
-
Gera, Germany, 07548
- Local Institution - 0211
-
Großhansdorf, Germany, 22927
- Local Institution - 0203
-
Halle, Germany, 06120
- Local Institution - 0209
-
Heidelberg, Germany, 69126
- Local Institution - 0202
-
Hemer, Germany, 58675
- Local Institution - 0214
-
Immenstadt im Allgäu, Germany, 87509
- Local Institution - 0206
-
München, Germany, 81925
- Local Institution - 0204
-
Stuttgart, Germany, 70376
- Local Institution - 0201
-
Wiesbaden, Germany, 65199
- Local Institution - 0212
-
-
Saxony-Anhalt
-
Magdeburg, Saxony-Anhalt, Germany, 39120
- Local Institution - 0231
-
-
-
-
-
Heraklion, Greece, 711 10
- Local Institution - 0095
-
Neo Faliro, Greece, 18547
- Local Institution - 0190
-
Thessaloniki, Greece, 54007
- Local Institution - 0101
-
-
Attikí
-
Athens, Attikí, Greece, 115 27
- Local Institution - 0094
-
-
-
-
-
Budapest, Hungary, 1083
- Local Institution - 0025
-
Budapest, Hungary, 1121
- Local Institution - 0024
-
Mátraháza, Hungary, 3233
- Local Institution - 0026
-
-
-
-
-
Beaumont, Ireland, Dublin 9
- Local Institution - 0053
-
Galway, Ireland
- Local Institution - 0055
-
Limerick, Ireland
- Local Institution - 0100
-
-
Dublin
-
Dublin, Dublin, Ireland
- Local Institution - 0054
-
-
-
-
-
Jerusalem, Israel, 91120
- Local Institution - 0187
-
Kfar Saba, Israel, 44281
- Local Institution - 0186
-
Petah Tikva, Israel, 49100
- Local Institution - 0185
-
Tel Litwinsky, Israel, 52621
- Local Institution - 0184
-
Ẕerifin, Israel, 70300
- Local Institution - 0188
-
-
-
-
-
Avellino, Italy, 83024
- Azienda Ospedaliera Moscati
-
Bergamo, Italy, 24127
- Local Institution - 0179
-
Bologna, Italy, 40138
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
-
Livorno, Italy, 57124
- Local Institution - 0084
-
Messina, Italy, 98125
- Policlinico G. Martino
-
Milan, Italy, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Napoli, Italy, 80131
- Istituto Nazionale Tumori Fondazione Pascale
-
Perugia, Italy, 06132
- Local Institution - 0087
-
Ravenna, Italy, 48121
- Ospedale Santa Maria delle Croci
-
Roma, Italy, 00161
- Local Institution - 0089
-
Roma, Italy, 00144
- Ifo-Istituto Regina Elena
-
Terni, Italy, 05100
- Local Institution - 0085
-
-
Lombardy
-
Milan, Lombardy, Italy, 20141
- Local Institution - 0083
-
-
-
-
-
Okayama, Japan, 700-8558
- Local Institution - 0165
-
Tokyo, Japan, 113-8603
- Local Institution - 0162
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 4600001
- Local Institution - 0153
-
Nagoya, Aichi-ken, Japan, 4648681
- Local Institution - 0152
-
-
Chiba
-
Chiba, Chiba, Japan, 260-8677
- Local Institution - 0260
-
Kashiwa-shi, Chiba, Japan, 2778577
- Local Institution - 0148
-
-
Ehime
-
Matsuyama, Ehime, Japan, 791-0280
- Local Institution - 0159
-
-
Fukuoka
-
Fukuoka, Fukuoka, Japan, 8120054
- Local Institution - 0160
-
Kurume-shi, Fukuoka, Japan, 8300011
- Local Institution - 0259
-
-
Gunma
-
Ota-shi, Gunma, Japan, 3730828
- Local Institution - 0255
-
-
Hiroshima
-
Hiroshima, Hiroshima, Japan, 7308518
- Local Institution - 0258
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 0030804
- Local Institution - 0163
-
Sapporo, Hokkaido, Japan, 0608648
- Local Institution - 0253
-
-
Hyōgo
-
Akashi-shi, Hyōgo, Japan, 6738558
- Local Institution - 0252
-
Kobe, Hyōgo, Japan, 6500047
- Local Institution - 0156
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, Japan, 9208641
- Local Institution - 0146
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 2210855
- Local Institution - 0161
-
Yokohama, Kanagawa, Japan, 2360051
- Local Institution - 0150
-
-
Miyagi
-
Natori-shi, Miyagi, Japan, 9811293
- Local Institution - 0275
-
Sendai, Miyagi, Japan, 9800873
- Local Institution - 0254
-
Sendai, Miyagi, Japan, 9808574
- Local Institution - 0145
-
-
Niigata
-
Niigata, Niigata, Japan, 9518566
- Local Institution - 0164
-
-
Okayama-ken
-
Kurashiki-shi, Okayama-ken, Japan, 7100052
- Local Institution - 0158
-
-
Osaka
-
Hirakata-shi, Osaka, Japan, 5731191
- Local Institution - 0155
-
Osaka, Osaka, Japan, 5340021
- Local Institution - 0154
-
Osakasayama-shi, Osaka, Japan, 5890014
- Local Institution - 0251
-
Takatsuki-shi, Osaka, Japan, 5698686
- Local Institution - 0257
-
-
Saitama
-
Hidaka-shi, Saitama, Japan, 3501298
- Local Institution - 0353
-
Kitaadachi-gun, Saitama, Japan, 3620806
- Local Institution - 0256
-
-
Shizuoka
-
Sunto-gun, Shizuoka, Japan, 4118777
- Local Institution - 0151
-
-
Tokyo
-
Chuo-ku, Tokyo, Japan, 1040045
- Local Institution - 0147
-
Koto-ku, Tokyo, Japan, 1358550
- Local Institution - 0149
-
Shinjuku-ku, Tokyo, Japan, 1600023
- Local Institution - 0278
-
-
Wakayama
-
Wakayama, Wakayama, Japan, 641-8510
- Local Institution - 0157
-
-
Yamaguchi
-
Ube-shi, Yamaguchi, Japan, 7550241
- Local Institution - 0354
-
-
-
-
-
Beirut, Lebanon, 00961
- Local Institution - 0287
-
Beirut, Lebanon, 166830
- Local Institution - 0286
-
-
-
-
-
Chihuahua City, Mexico, 31217
- Local Institution - 0192
-
San Luis Potosí City, Mexico, 78200
- Local Institution - 0195
-
San Luis Potosí City, Mexico, 78213
- Local Institution - 0236
-
Toluca, Mexico, 50180
- Local Institution - 0194
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44270
- Local Institution - 0197
-
Zapopan, Jalisco, Mexico, 44280
- Local Institution - 0191
-
-
Mexico City
-
Df, Mexico City, Mexico, 06720
- Local Institution - 0196
-
Mexico City, Mexico City, Mexico, 14080
- Local Institution - 0193
-
-
Michoacán
-
Morelia, Michoacán, Mexico, 58000
- Local Institution - 0267
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64060
- Local Institution - 0277
-
-
State of Mexico
-
Cuautitlán, State of Mexico, Mexico, 54769
- Local Institution - 0198
-
-
Yucatán
-
Mérida, Yucatán, Mexico, 97070
- Local Institution - 0303
-
-
-
-
-
Amsterdam, Netherlands, 1066 CX
- Local Institution - 0036
-
Amsterdam, Netherlands, 1081 HV
- Local Institution - 0189
-
Breda, Netherlands, 4818 CK
- Local Institution - 0169
-
Rotterdam, Netherlands, 3014 GD
- Local Institution - 0037
-
Veldhoven, Netherlands, 5504 DB
- Local Institution - 0039
-
-
-
-
-
Lima, Peru
- Local Institution - 0262
-
Lima, Peru
- Local Institution - 0263
-
Lima, Peru, 27
- Local Institution - 0350
-
Lima, Peru, 34
- Local Institution - 0261
-
Lima, Peru, Lima 41
- Local Institution - 0351
-
-
-
-
-
Bydgoszcz, Poland, 85-796
- Local Institution - 0060
-
Gdansk, Poland, 80-19
- Local Institution - 0058
-
Gdynia, Poland, 81-519
- Local Institution - 0063
-
Gliwice, Poland, 44-101
- Local Institution - 0072
-
Lodz, Poland, 93-513
- Local Institution - 0057
-
Warsaw, Poland, 02-781
- Local Institution - 0059
-
Wroclaw, Poland, 52-229
- Local Institution - 0070
-
-
-
-
-
Craiova, Romania, 200542
- Local Institution - 0167
-
Floreşti, Romania, 407280
- Local Institution - 0250
-
Romania, Romania, 400015
- Local Institution - 0166
-
Sector 2, Romania, 022328
- Local Institution - 0284
-
-
-
-
-
Chelyabinsk, Russia, 454048
- Local Institution - 0137
-
Kazan', Russia, 420029
- Local Institution - 0142
-
Moscow, Russia, 115478
- Local Institution - 0022
-
Saint Petersburg, Russia, 194291
- Local Institution - 0028
-
Saint Petersburg, Russia, 197758
- Local Institution - 0049
-
Saint Petersburg, Russia, 198255
- Local Institution - 0027
-
Ufa, Russia, 450054
- Local Institution - 0143
-
-
-
-
-
Vereeniging, South Africa, 1936
- Local Institution - 0305
-
-
Gauteng
-
Pretoria, Gauteng, South Africa, 0002
- Local Institution - 0264
-
Sandton, Gauteng, South Africa, 2196
- Local Institution - 0234
-
Saxonwold, Johannesburg, Gauteng, South Africa, 2196
- Local Institution - 0233
-
-
-
-
-
Cheongju-si, South Korea, 28644
- Local Institution - 0249
-
Gangnam-gu, South Korea, 06351
- Local Institution - 0133
-
Seoul, South Korea, 05505
- Local Institution - 0132
-
Seoul, South Korea, 06591
- Local Institution - 0135
-
-
Kyǒnggi-do
-
Seongnam-si, Kyǒnggi-do, South Korea, 436-707
- Local Institution - 0136
-
-
-
-
-
Barcelona, Spain, 08035
- Local Institution - 0066
-
Barcelona, Spain, 08916
- Local Institution - 0067
-
Madrid, Spain, 28041
- Local Institution - 0065
-
Seville, Spain, 41013
- Local Institution - 0069
-
Valencia, Spain, 46014
- Local Institution - 0068
-
-
Madrid
-
Majadahonda, Madrid, Spain, 28222
- Local Institution - 0064
-
-
-
-
-
Basel, Switzerland, 4031
- Local Institution - 0243
-
Chur, Switzerland, 7000
- Local Institution - 0246
-
Lausanne, Switzerland, 1011
- Local Institution - 0244
-
Winterthur, Switzerland, 8401
- Local Institution - 0245
-
-
-
-
-
Taichung, Taiwan, 407
- Local Institution - 0139
-
Taipei, Taiwan, 100
- Local Institution - 0138
-
Taipei, Taiwan, 112
- Local Institution - 0140
-
Taipei, Taiwan, 235
- Local Institution - 0310
-
Taoyuan, Taiwan, 333
- Local Institution - 0141
-
-
-
-
-
Birmingham, United Kingdom, B4 6DHH
- Local Institution - 0265
-
Cambridgeshire, United Kingdom, CB2 2QQ
- Local Institution - 0051
-
Edinburgh, United Kingdom, EH4 2XU
- Local Institution - 0109
-
London, United Kingdom, N18 1QX
- Local Institution - 0097
-
London, United Kingdom, SE1 9RT
- Local Institution - 0050
-
Surrey, United Kingdom, SM2 5PT
- Local Institution - 0119
-
-
Cleveland
-
Middlesbrough, Cleveland, United Kingdom, TS4 3BW
- Local Institution - 0266
-
-
Greater London
-
London, Greater London, United Kingdom, SW3 6JJ
- Local Institution - 0098
-
-
Hampshire
-
Southampton, Hampshire, United Kingdom, SO16 0YD
- Local Institution - 0099
-
-
Leicestershire
-
Leicester, Leicestershire, United Kingdom, LE1 5WW
- Local Institution - 0118
-
-
-
-
Alabama
-
Mobile, Alabama, United States, 36608
- Southern Cancer Center, Inc.
-
-
California
-
San Francisco, California, United States, 94115
- Local Institution - 0017
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Local Institution - 0021
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Local Institution - 0001
-
Marietta, Georgia, United States, 30060
- Local Institution - 0013
-
-
Kentucky
-
Lexington, Kentucky, United States, 40503
- Local Institution - 0004
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Local Institution - 0115
-
-
New York
-
Buffalo, New York, United States, 14263
- Local Institution - 0005
-
New York, New York, United States, 10065
- Local Institution - 0019
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Local Institution - 0014
-
Columbus, Ohio, United States, 43210
- Local Institution - 0009
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18103
- Local Institution - 0007
-
Langhorne, Pennsylvania, United States, 19047
- Local Institution - 0075
-
Philadelphia, Pennsylvania, United States, 19107
- Local Institution - 0299
-
Philadelphia, Pennsylvania, United States, 19111-2412
- Local Institution - 0012
-
Sayre, Pennsylvania, United States, 18840
- Local Institution - 0015
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Local Institution - 0008
-
Greenville, South Carolina, United States, 29605
- Local Institution - 0080
-
Greenville, South Carolina, United States, 29607
- Local Institution - 0010
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Local Institution - 0020
-
-
Texas
-
Dallas, Texas, United States, 75390-8852
- Local Institution - 0306
-
Dallas, Texas, United States, 75390
- Local Institution - 0003
-
Houston, Texas, United States, 77030
- Local Institution - 0102
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- Local Institution - 0011
-
-
Washington
-
Kennewick, Washington, United States, 99336
- Local Institution - 0074
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects with histologically confirmed Stage IV or recurrent NSCLC squamous or non-squamous histology, with no prior systemic anticancer therapy
- Subjects must have programmed death-ligand 1 (PD -L1) immunohistochemical (IHC) testing, with results, performed by the central lab during the Screening period
- Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1
- Measurable disease by CT or MRI per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteria
Exclusion Criteria:
- Subjects with untreated Central nervous system (CNS) metastases are excluded
- Subjects with an active, known or suspected autoimmune disease are excluded
- Any positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) indicating acute or chronic infection
Other protocol defined inclusion/exclusion criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm A: Nivolumab
Nivolumab intravenously (IV) as specified
|
Other Names:
|
|
Experimental: Arm B: Nivolumab + Ipilimumab
Nivolumab + Ipilimumab IV as specified
|
Other Names:
Other Names:
|
|
Experimental: Arm C: Nivolumab + Platinum doublet chemotherapy
Nivolumab + Platinum doublet chemotherapy (IV) dose as specified
|
Other Names:
|
|
Experimental: Arm D: Platinum doublet chemotherapy
Chemotherapy administered on specified days of IV chemotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-Free Survival Per BICR
Time Frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 481 weeks)
|
Progression-Free Survival then (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first based on Kaplan-Meier estimates.
Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study).
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
|
From randomization untill disease progression or death, whichever occurs first (up to approximately 481 weeks)
|
|
Overall Survival
Time Frame: From randomization untill death or last follow up whichever occurs first (up to approximately 481 weeks)
|
OS for all randomized participants is the time between randomization date and the date of death from any cause.
|
From randomization untill death or last follow up whichever occurs first (up to approximately 481 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response Rate (ORR) Per BICR
Time Frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 481 weeks)
|
Objective response rate (ORR) is defined as the number of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
From randomization untill disease progression or death, whichever occurs first (up to approximately 481 weeks)
|
|
Percentage of Participants With Symptom Deterioration at Week 12 Assessed Via Lung Cancer Symptom Scale
Time Frame: Week 12
|
The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life.
This patient reported outcome (PRO) questionnaire assesses the following 6 symptoms items (appetite loss, fatigue, cough, dyspnea, hemoptysis, pain) and 3 summary global items (symptom distress, activity level, overall quality of life) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating).
The LCSS average total score is sum of items 1 to 9 divided by the total number of items ((sum of items 1 to 9)/9) ranging from 0 to 100 where high score represent worst outcome.
Disease-Related Symptom Deterioration by Week 12 defined as a 10 points or more increase from baseline in LCSS average score at any time (on or off-treatment) up to 95 days from randomization date.
|
Week 12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
General Publications
- Reck M, Ciuleanu TE, Lee JS, Schenker M, Audigier-Valette C, Zurawski B, Linardou H, Otterson GA, Salman P, Nishio M, de la Mora Jimenez E, Lesniewski-Kmak K, Albert I, Ahmed S, Syrigos K, Penrod JR, Yuan Y, Blum SI, Nathan FE, Sun X, Moreno-Koehler A, Taylor F, O'Byrne KJ. First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1. J Thorac Oncol. 2021 Apr;16(4):665-676. doi: 10.1016/j.jtho.2020.12.019. Epub 2021 Jan 21.
- Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.
- Reck M, Schenker M, Lee KH, Provencio M, Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney K, Corre R, Franke FA, Richardet E, Penrod JR, Yuan Y, Nathan FE, Bhagavatheeswaran P, DeRosa M, Taylor F, Lawrance R, Brahmer J. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. Eur J Cancer. 2019 Jul;116:137-147. doi: 10.1016/j.ejca.2019.05.008. Epub 2019 Jun 11.
- Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O'Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
- Peters S, Paz-Ares LG, Reck M, Carbone DP, Brahmer JR, Borghaei H, Lu S, O'Byrne KJ, John T, Ciuleanu TE, Schenker M, Bernabe Caro R, Nishio M, Cobo M, Lee JS, Zurawski B, Pluzanski A, Aoyama T, Tschaika M, Devas V, Grootendorst DJ, Ramalingam SS. Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis. J Thorac Oncol. 2025 Jan;20(1):94-108. doi: 10.1016/j.jtho.2024.09.1439. Epub 2024 Oct 4.
- Mason M, Lapuente-Santana O, Halkola AS, Wang W, Mall R, Xiao X, Kaufman J, Fu J, Pfeil J, Banerjee J, Chung V, Chang H, Chasalow SD, Lin HY, Chai R, Yu T, Finotello F, Mirtti T, Mayranpaa MI, Bao J, Verschuren EW, Ahmed EI, Ceccarelli M, Miller LD, Monaco G, Hendrickx WRL, Sherif S, Yang L, Tang M, Gu SS, Zhang W, Zhang Y, Zeng Z, Das Sahu A, Liu Y, Yang W, Bedognetti D, Tang J, Eduati F, Laajala TD, Geese WJ, Guinney J, Szustakowski JD, Vincent BG, Carbone DP. A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer. J Transl Med. 2024 Feb 21;22(1):190. doi: 10.1186/s12967-023-04705-3.
- Brahmer JR, Lee JS, Ciuleanu TE, Bernabe Caro R, Nishio M, Urban L, Audigier-Valette C, Lupinacci L, Sangha R, Pluzanski A, Burgers J, Mahave M, Ahmed S, Schoenfeld AJ, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Gupta RG, Bushong J, Li L, Blum SI, Eccles LJ, Ramalingam SS. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. J Clin Oncol. 2023 Feb 20;41(6):1200-1212. doi: 10.1200/JCO.22.01503. Epub 2022 Oct 12.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Amino Acids, Peptides, and Proteins
- Proteins
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Hydrocarbons
- Cycloparaffins
- Hydrocarbons, Alicyclic
- Hydrocarbons, Cyclic
- Terpenes
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Inorganic Chemicals
- Chlorine Compounds
- Nitrogen Compounds
- Coordination Complexes
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamates
- Amino Acids, Acidic
- Amino Acids
- Amino Acids, Dicarboxylic
- Taxoids
- Cyclodecanes
- Diterpenes
- Deoxycytidine
- Cytidine
- Pyrimidine Nucleosides
- Pyrimidines
- Platinum Compounds
- Nivolumab
- Pemetrexed
- Ipilimumab
- Gemcitabine
- Carboplatin
- Paclitaxel
- Cisplatin
Other Study ID Numbers
- CA209-227
- 2014-003630-23 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of California, DavisNational Cancer Institute (NCI)RecruitingNon Small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IV | Non-small Cell Lung Cancer Stage IIIC | Non-small Cell Lung Cancer UnresectableUnited States
-
Royal Marsden NHS Foundation TrustUniversity of Cambridge; Royal Brompton & Harefield NHS Foundation Trust; Institute... and other collaboratorsRecruitingNon Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Locally Advanced NSCLC - Non-Small Cell Lung Cancer | Oncogene-addicted Non Small Cell Lung Cancer | Early-stage Operable Non Small Cell Lung Cancer | Stage 2/3 Operable Non Small Cell Lung CancerUnited Kingdom
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbTerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
Brigham and Women's HospitalFood and Drug Administration (FDA)Active, not recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Advanced Squamous Non Small Cell Lung CancerUnited States
-
Jiangxi Provincial People's HopitalNot yet recruitingNon-Small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV | Non-small Cell Lung Cancer RecurrentChina
Clinical Trials on Gemcitabine
-
Shanghai University of Traditional Chinese MedicineNot yet recruiting
-
Ankara UniversityTurkish Oncology GroupActive, not recruitingBiliary Tract Cancer | Biliary Tract Cancers (BTC)Turkey
-
Sierra Oncology LLC - a GSK companyCompletedAdvanced Solid TumorsSpain, United Kingdom
-
AstraZenecaActive, not recruitingBiliary Tract CancerFrance, Italy, Spain, United States, Japan, Singapore, Germany, South Korea
-
Assiut UniversityActive, not recruiting
-
Shanghai 6th People's HospitalRecruiting
-
Swiss Cancer InstituteNot yet recruitingNSCLC | NSCLC (Advanced Non-small Cell Lung Cancer)Switzerland
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Shenzhen University General HospitalNot yet recruiting
-
Tianjin Medical University Cancer Institute and...Not yet recruiting